pnifty3 n lucia reporter gene (InvivoGen)
InvivoGen is a verified supplier 
InvivoGen manufactures this product 
92
Structured Review
InvivoGen
pnifty3 n lucia reporter gene
Pnifty3 N Lucia Reporter Gene, supplied by InvivoGen, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pnifty3+n+lucia+reporter+gene/pNiFty3-N-Lucia/pm38850654-49-22-25
Average 92 stars, based on 1 article reviews
Pnifty3 N Lucia Reporter Gene, supplied by InvivoGen, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pnifty3+n+lucia+reporter+gene/pNiFty3-N-Lucia/pm38850654-49-22-25
Average 92 stars, based on 1 article reviews
pnifty3 n lucia reporter gene - by Bioz Stars,
2026-10
92/100 stars
Images
Related Articles
Generated:Article Title: Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin α-FAPx4-1BB: A preclinical study in multiple myeloma. Article Snippet: Multiple myeloma (MM) progression is closely dependent on cells in the bone marrow (BM) microenvironment, including fibroblasts (FBs) and immune cells.. In their BM niche, MM cells adhere to FBs sustaining immune evasion, drug resistance and the undetectable endurance of tumor cells known as minimal residual disease (MRD).. Here, we describe the novel bi-specific designed ankyrin repeat protein (DARPin) α-FAPx4–1BB (MP0310) with FAP-dependent 4–1BB agonistic activity. Stable Transfection:Article Title: Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin α-FAPx4-1BB: A preclinical study in multiple myeloma. Article Snippet: Multiple myeloma (MM) progression is closely dependent on cells in the bone marrow (BM) microenvironment, including fibroblasts (FBs) and immune cells.. In their BM niche, MM cells adhere to FBs sustaining immune evasion, drug resistance and the undetectable endurance of tumor cells known as minimal residual disease (MRD).. Here, we describe the novel bi-specific designed ankyrin repeat protein (DARPin) α-FAPx4–1BB (MP0310) with FAP-dependent 4–1BB agonistic activity. |